rbm39 degrader rec-1245

Generic: RBM39 Degrader REC-1245

rbm39 degrader rec-1245: sourced relationships with 1 company · 1 clinical trial tracked.

What we can confirm

1 tracked trial

What it means

Source-backed records connect rbm39 degrader rec-1245 to RXRX; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.

BioSniper AIPage evidence connected

Prepared research question

How could rbm39 degrader rec-1245 → RXRX affect its developer, and what evidence supports the link?

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Unresectable

No additional listed-company sponsor is linked.

Dated Pipeline Records (1)

Company	Dated record stage	Indication
RECURSION PHARMACEUTICALS, INC. (RXRX) owner · Reported 2025-02-28 · Current development: unknownSource Unresectable	Phase 1/Phase 2	Unresectable

Clinical Trial Registry Records (1)

A Phase 1 / 2, Open-Label Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer

NCT06678659Registry updated 2026-08-20·Phase 1/Phase 2·RXRX

Recruiting

Primary endpoint: Phase 1-Part 1A (Dose Finding)- Number of Participants With Dose Limiting Toxicities (DLTs)

InterventionalRandomizedopen170 targetStarted 2024-11Completion 2028-107 sites · Canada, United StatesRecursion Pharmaceuticals Inc.

Frequently asked questions

rbm39 degrader rec-1245 has dated SEC/FDA relationship records for RECURSION PHARMACEUTICALS, INC..

BioSniper tracks 1 clinical trial involving rbm39 degrader rec-1245.